Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) has begun Phase 2 clinical testing of PH-10, the company’s topical drug for dermatology, for the treatment of atopic dermatitis, a chronic skin condition that includes some forms of eczema. The study is designed to evaluate efficacy of PH-10 in a total of twenty subjects with mild to severe forms of the disease. In the study, subjects will apply PH-10 daily for up to four weeks to their skin areas affected by atopic dermatitis.

This post is an original post by ScienceDaily: Skin Care News